Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sodium cromoglicate inhalant - Respivant Sciences

Next Previous
Drug Profile

Sodium cromoglicate inhalant - Respivant Sciences

Alternative Names: Cromolyn sodium - Patara Pharma; Disodium cromoglicate; PA-101; PA-101B; RVT-1601; Sodium cromoglicate inhalant - Patara Pharma

Latest Information Update: 28 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Patara Pharma
  • Developer Patara Pharma; Respivant Sciences
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antitussives; Benzopyrans; Chromones; Nootropics; Small molecules
  • Mechanism of Action Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Mastocytosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pruritus; Systemic mastocytosis
  • No development reported Cough; Respiratory tract disorders

Most Recent Events

  • 28 Nov 2022 No recent reports of development identified for phase-I development in Respiratory-tract-disorders(In neonates) in USA (Inhalation, Aerosol)
  • 28 Sep 2022 No development reported - Phase-II for Cough in United Kingdom, Netherlands, USA, Australia, Belgium, Canada, Czech Republic, Germany, Italy, New Zealand, Turkey (Inhalation)
  • 11 Jun 2020 Respivant Sciences terminates the phase IIb SCENIC trial in Cough in Australia, Belgium, Canada, Czech Republic, Germany, Italy, New Zealand, Turkey, Netherlands and United Kingdom due to COVID-19 pandemic (Inhalation) (NCT03864328)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top